Methamphetamine-like Discriminative-stimulus Effects of Nicotinic Agonists
Overview
Authors
Affiliations
Nicotine was recently shown to engender d-methamphetamine (MA)-like discriminative-stimulus effects in rats, which may be indicative of shared psychomotor stimulant properties. To further investigate such overlapping discriminative-stimulus effects, nicotinic agonists varying in efficacy and selectivity were studied in squirrel monkeys that discriminated a moderate intramuscular dose of MA (0.1 mg/kg) from vehicle. These included α4β2-selective ligands that may vary in efficacy from relatively high [nicotine, (+)- and (-)-epibatidine] to relatively low [isoarecolone, varenicline, (-)-cytisine, (-)-lobeline] and the α7-selective ligands anabaseine and anabasine. Results show that nicotine, (+)-epibatidine, and (-)-epibatidine substituted fully for MA, whereas the highest doses of other nicotinic agonists produced intermediate levels of MA-like effects (isoarecolone, anabaseine, anabasine, and varenicline) or did not substitute for MA [(-)-cytisine and (-)-lobeline]. The relative potencies of nicotinic agonists, based on effective dose50 (ED50) values, corresponded more closely with their relative affinities at α4β2 than at α7 receptors. Regardless of selectivity or efficacy, nicotinic agonists also were observed to produce untoward effects, including salivation and emesis during or after experimental sessions. In pretreatment studies, the α4β2-selective antagonist dihydro-β-erythroidine hydrobromide (DHβE) (0.032 and 0.1 mg/kg) and the partial agonists varenicline (0.0032-0.1 mg/kg) and (-)-cytisine (0.032 and 0.1 mg/kg) surmountably antagonized (>10-fold rightward shift) nicotine's MA-like effects but were ineffective in blocking nicotine's emetic effects. Overall, our results show that 1) MA-like discriminative-stimulus effects of nicotinic agonists likely are mediated through α4β2 nicotinic acetylcholine receptor actions, and 2) nicotinic α4β2 partial agonists, like the nicotinic antagonist DHβE, can reduce MA-like behavioral effects of nicotine.
Burke E, Desai R Drug Alcohol Depend. 2024; 258:111280.
PMID: 38614019 PMC: 11117166. DOI: 10.1016/j.drugalcdep.2024.111280.
The Common Denominators of Parkinson's Disease Pathogenesis and Methamphetamine Abuse.
Vincent B, Shukla M Curr Neuropharmacol. 2023; 22(13):2113-2156.
PMID: 37691228 PMC: 11337683. DOI: 10.2174/1570159X21666230907151226.
Withey S, Doyle M, Bergman J, Desai R J Pharmacol Exp Ther. 2018; 366(2):397-409.
PMID: 29784663 PMC: 6053592. DOI: 10.1124/jpet.118.248070.
Kangiser M, Dwoskin L, Zheng G, Crooks P, Stairs D Behav Pharmacol. 2017; 29(1):87-97.
PMID: 28863003 PMC: 5760454. DOI: 10.1097/FBP.0000000000000340.
Effects of Nicotine Metabolites on Nicotine Withdrawal Behaviors in Mice.
Elhassan S, Bagdas D, Damaj M Nicotine Tob Res. 2017; 19(6):763-766.
PMID: 28199726 PMC: 5423097. DOI: 10.1093/ntr/ntx045.